Views & Analysis Promise for combination approach to cancer As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
News AZ pays Heptares $10m as cancer trial begins Phase 1 study of immuno-oncology drug candidate begins.
R&D BMS looks for cancer combos with Cormorant buy Bristol searching for new immuno-oncology combinations.
News Novartis buys into bispecific antibodies with Xencor deal Agreement could add to Novartis' immuno-oncology pipeline.
Cancer Novartis' Afinitor gets new EU cancer use Novartis’ Afinitor has been approved in a new cancer indication in Europe – but faces potential competition from newer drugs.
News Amgen scores with new thyroid eye disease formulation Can Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
